CN-122012326-A - Streptococcus stomatitis ZRSOR and related products, methods and uses thereof

CN122012326ACN 122012326 ACN122012326 ACN 122012326ACN-122012326-A

Abstract

The invention provides streptococcus stomatitis ZRSOR and related products, methods and applications thereof. The oral streptococcus (Streptococcus oralis) ZRSOR-5 provided by the invention has a preservation number of GDMCC No:65352 in the Guangdong province microorganism strain collection center. Experiments prove that the SOR preparation is prepared by diluting with normal saline and inhaling into mice in advance, so that the survival rate of mice infected with influenza virus can be remarkably improved, and lung inflammation and viral load can be reduced. The ZRSOR-5 preparation provided by the invention can resist pneumonia caused by influenza viruses when being used in advance.

Inventors

CAO BIN
ZOU XIAOHUI
LIU BO

Assignees

中日友好医院(中日友好临床医学研究所)

Dates

Publication Date: 20260512
Application Date: 20250116

Claims (7)

1. Streptococcus, characterized in that the Streptococcus is Streptococcus stomatitis (Streptococcus oralis) ZRSOR-5 deposited under accession number GDMCC No:65352 in the microorganism culture Collection of Guangdong province.
2. The composition is characterized in that, the composition comprises the streptococcus of claim 1.
3. The composition according to claim 2, wherein the composition is a culture which is obtained by culturing the Streptococcus in a microbial medium.
4. The composition of claim 2, wherein the composition is a microbial inoculum.
5. A method for preparing a composition, characterized in that the composition is a composition according to any one of claims 2-4, comprising the step of taking the streptococcus according to claim 1as a component of the composition.
6. Use of a streptococcus of claim 1 or a composition of any of claims 2-4 for the manufacture of a medicament, wherein the medicament has at least one of the following properties: b1 Preventing and treating viral pneumonia caused by viral infection; b2 Reducing viral load following viral infection; B3 Limiting viral infection; B4 Improving survival rate after virus infection; B5 Reducing the magnitude of weight loss following viral infection; b6 Increasing expression of immunomodulatory genes following viral infection; b7 Inhibiting viral transmission following viral infection; b8 Reducing lung injury caused by the virus; b9 Reducing injury to alveolar capillary barriers following viral infection; B10 Improving alveolar capillary membrane permeability after viral infection; b11 Reducing pulmonary inflammation after viral infection; b12 Reducing the level of inflammatory markers IL-6 following viral infection; B13 Reducing the level of inflammatory markers TNF- α following viral infection; B14 Reducing viral infiltration of inflammatory cells; B15 Promoting the timely activation of the innate immune response to the virus; b16 Preventing immune-mediated pathological damage after viral infection.
7. The use according to claim 6, wherein the product is an intranasal and/or an intra-airway inhalational inoculation.

Description

Streptococcus stomatitis ZRSOR and related products, methods and uses thereof The invention relates to a Chinese patent application with the application date of 2025, 01, 16, the application number of 202510066374.1 and the name of oral streptococcus ZRSOR-5 and related products, methods and applications. Technical Field The invention relates to the technical field of microorganisms, and particularly discloses streptococcus stomatitis ZRSOR and related products, methods and applications thereof. Background Community-acquired pneumonia (CAP) is a pulmonary infection disease that occurs outside hospitals, with higher morbidity and mortality, especially in elderly, infants and people with past health problems. Traditional treatment strategies for CAP have focused mainly on eliminating disease-causing pathogens, however, studies have shown that less than 50% of CAP patients are able to detect typical pathogens, suggesting a significant role for other respiratory microorganisms in CAP pathogenesis. In recent years, more and more studies have found that the balance of the respiratory microbiota is critical to the health of the respiratory tract. Microbiota dysregulation, i.e. a decrease in microbial diversity and excessive proliferation of potential pathogenic bacteria, is closely related to the development of respiratory diseases such as CAP. Studies have shown that CAP patients generally exhibit lower microbial diversity, increased bacterial load, and enrichment of streptococcus and veillonella. In patients with partial severe infections such as sepsis and Acute Respiratory Distress Syndrome (ARDS), studies have also found that the intestinal-related bacteria in the pulmonary microbiota are enriched and significantly associated with the pulmonary inflammatory mediator TNF- α. However, there is currently no systematic study on CAP and immune modulation against respiratory symbiotic bacteria, nor is there any discovery of a critical symbiotic bacterial class. Disclosure of Invention The application aims to solve the technical problems of improving the survival rate of influenza virus after infection and reducing lung inflammation and viral load. In order to solve the technical problems, the invention provides streptococcus which is streptococcus stomatitis (Streptococcus oralis) ZRSOR-5 and has a preservation number of GDMCC No:65352 in the Guangdong province microorganism strain preservation center for the first time. The invention also provides a composition containing the streptococcus. The composition may be a culture, which is a substance obtained by culturing the streptococcus in a microbial medium. The active ingredient of the composition can be the streptococcus or/and the metabolite of the streptococcus or/and the culture of the streptococcus. The metabolites may be obtained from the shake culture of Streptococcus. The metabolite may be a bacteria-containing metabolite of the streptococcus. The culture may be a substance obtained by culturing the streptococcus in a microbial medium. The substance may be a fermentation product, such as a fermentation broth, which contains the streptococcus and the substances secreted into the liquid medium, or a solid fermentation, which contains the streptococcus and the substances secreted into the solid medium. The composition may also be a microbial agent. The active ingredient of the microbial agent may also contain other biological or non-biological components, which may be determined by one skilled in the art based on the effectiveness of the microbial agent. The microbial agent is a living microbial agent prepared by processing fermentation liquor or solid fermentation products of adsorbed bacteria by using a carrier as an adsorbent after target microorganisms are propagated. Among the above bacterial agents, the formulation of the bacterial agent can be various formulations including, but not limited to, liquid, emulsion, suspension, powder, granule, wettable powder or water dispersible granule. The microbial inoculum can also comprise a carrier according to requirements. The carrier may be a solid carrier or a liquid carrier. The carrier may comprise a pharmaceutically acceptable carrier. The carrier materials include, but are not limited to, water soluble carrier materials (e.g., polyethylene glycol, polyvinylpyrrolidone, organic acids, etc.), poorly soluble carrier materials (e.g., ethylcellulose, cholesterol stearate, etc.), enteric carrier materials (e.g., cellulose acetate phthalate, carboxymethyl ethyl cellulose, etc.). Among them, preferred is a water-soluble carrier material. The materials can be prepared into various dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, microspheres, transdermal agents, buccal tablets, suppositories, freeze-dried powder injection and the like. Can be common preparation, slow release preparation, controlled release p